Infinity Pharmaceuticals Inc. (NASDAQ:INFI) – Research analysts at William Blair raised their Q2 2017 earnings per share estimates for Infinity Pharmaceuticals in a note issued to investors on Tuesday. William Blair analyst Y. Xu now forecasts that the biotechnology company will post earnings per share of ($0.21) for the quarter, up from their prior estimate of ($0.23). William Blair also issued estimates for Infinity Pharmaceuticals’ Q3 2017 earnings at ($0.21) EPS, Q4 2017 earnings at ($0.21) EPS, FY2017 earnings at ($0.84) EPS, FY2018 earnings at ($0.73) EPS and FY2019 earnings at ($0.58) EPS.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 125.20%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $19.60 million. During the same quarter in the prior year, the company posted ($0.82) earnings per share. Infinity Pharmaceuticals’s revenue for the quarter was down 99.9% compared to the same quarter last year.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) opened at 1.81 on Friday. The stock’s market cap is $91.27 million. The company’s 50-day moving average is $2.40 and its 200-day moving average is $1.98. Infinity Pharmaceuticals has a 52-week low of $0.84 and a 52-week high of $5.79.
Several hedge funds have recently modified their holdings of the company. Teachers Advisors LLC increased its stake in shares of Infinity Pharmaceuticals by 10.4% in the first quarter. Teachers Advisors LLC now owns 117,028 shares of the biotechnology company’s stock valued at $378,000 after buying an additional 11,067 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Infinity Pharmaceuticals by 4.8% in the first quarter. Wellington Management Group LLP now owns 4,565,947 shares of the biotechnology company’s stock valued at $14,748,000 after buying an additional 207,876 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Infinity Pharmaceuticals by 0.3% in the first quarter. Bank of New York Mellon Corp now owns 170,649 shares of the biotechnology company’s stock valued at $551,000 after buying an additional 443 shares in the last quarter. Algert Global LLC bought a new stake in shares of Infinity Pharmaceuticals during the first quarter valued at $129,000. Finally, Wells Fargo & Company MN increased its stake in shares of Infinity Pharmaceuticals by 144.6% in the first quarter. Wells Fargo & Company MN now owns 81,493 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 48,177 shares in the last quarter. Institutional investors and hedge funds own 79.56% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.